Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00942981|
Recruitment Status : Recruiting
First Posted : July 21, 2009
Last Update Posted : September 19, 2018
- Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. People with schizophrenia have difficulty thinking and experience hallucinations and delusions. Medications that change brain dopamine receptors can decrease these hallucinations and delusions.
- The cause of schizophrenia and its association with brain dopamine receptors is not known but may be clarified by studying dopamine receptors in people who have dopamine disorders (such as schizophrenia) and those who do not. Researchers are interested in studying the dopamine system to gain a better idea of how dopamine disorders develop, which may lead to better medical care for people with schizophrenia.
- To study the amount and distribution of two types of dopamine receptors.
- Individuals between the ages of 18 and 60 who have schizophrenia.
- Healthy volunteers between the ages of 18 and 90.
- Participants will undergo a full screening, with physical and psychological history, a neurological examination, and blood and urine samples.
- Participants will have a blood flow map of the brain recorded with a positron emission tomography (PET) brain scan. A magnetic resonance imaging (MRI) scan will also be performed to determine brain anatomy.
- To study the amount and distribution of dopamine receptors in the brain, participants will receive a small amount of a radioactive chemical in the vein, followed by a PET scan.
- The procedure will be performed twice in two separate sessions, once for [18F]fallypride and once for [11C]NNC-112.
|Condition or disease|
|Schizoaffective Disorder Schizophrenia|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||330 participants|
|Official Title:||Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography|
|Study Start Date :||July 17, 2009|
- Regional binding potentials of [11C]NNC-112 and [18F]Fallypride
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00942981
|Contact: Jasmin Czarapata, Ph.D.||(301) firstname.lastname@example.org|
|Contact: Karen F Berman, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Karen F Berman, M.D.||National Institute of Mental Health (NIMH)|